Imatinib effect on growth and signal transduction in polycythemia vera

Amos Gaikwad, Srdan Verstovsek, Donghoon Yoon, Ko Tung Chang, Taghi Manshouri, Roberto Nussenzveig, Jorge Cortes, William Vainchenker, Josef T. Prchal

Research output: Contribution to journalArticle

Abstract

Objective: An activating mutation of Janus kinase 2 (JAK2) in majority of polycythemia vera (PV) and other myeloproliferative disorders was reported. As imatinib inhibits several tyrosine kinases, we studied its effect in PV. Patients and Methods: We employed FDCP reporter cells expressing wild-type JAK2 and mutant JAK2V617F to study the efficacy of imatinib by cell proliferation assay and its effect on several cell-signaling events. Imatinib's efficacy was also examined on in vitro expanded native human erythroid progenitors. In addition, analysis of the percent JAK2 T-allele and phospho-signal transducer and activator of transcription-5 (STAT5) in granulocytes of PV patients following imatinib therapy was assessed. Results: Imatinib showed a specific time- and dose-dependent growth inhibitory effect on FDCP cells expressing JAK2V617F, wherein we observed imatinib's inactivation of JAK2, STAT5 and cKIT proteins. In vitro expanded human PV erythroid progenitors were more sensitive to imatinib than normal erythroid progenitors and FDCP cells expressing JAK2V617F, with growth inhibition at concentrations attainable in vivo. In an ongoing clinical study, a PV patient showed strong correlation between the percent JAK2 T-allele and his responsiveness to imatinib therapy. Conclusion: Our data elucidate the therapeutic benefit of imatinib seen in some PV patients. Our data suggest that JAK2/STAT5 and cKIT activation may be integrated. To our knowledge, this is the first report demonstrating imatinib's effect on PV erythroid progenitors. These studies underscore the limitation of experiments using cell lines expressing the gene of interest.

Original languageEnglish (US)
Pages (from-to)931-938
Number of pages8
JournalExperimental Hematology
Volume35
Issue number6
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

Fingerprint

Polycythemia Vera
Janus Kinase 2
Signal Transduction
Growth
STAT5 Transcription Factor
Alleles
Imatinib Mesylate
Myeloproliferative Disorders
Erythroid Precursor Cells
Population Groups
Granulocytes
Protein-Tyrosine Kinases
Therapeutics
Cell Proliferation
Cell Line

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Genetics
  • Cell Biology
  • Cancer Research

Cite this

Gaikwad, A., Verstovsek, S., Yoon, D., Chang, K. T., Manshouri, T., Nussenzveig, R., ... Prchal, J. T. (2007). Imatinib effect on growth and signal transduction in polycythemia vera. Experimental Hematology, 35(6), 931-938. https://doi.org/10.1016/j.exphem.2007.03.012

Imatinib effect on growth and signal transduction in polycythemia vera. / Gaikwad, Amos; Verstovsek, Srdan; Yoon, Donghoon; Chang, Ko Tung; Manshouri, Taghi; Nussenzveig, Roberto; Cortes, Jorge; Vainchenker, William; Prchal, Josef T.

In: Experimental Hematology, Vol. 35, No. 6, 01.06.2007, p. 931-938.

Research output: Contribution to journalArticle

Gaikwad, A, Verstovsek, S, Yoon, D, Chang, KT, Manshouri, T, Nussenzveig, R, Cortes, J, Vainchenker, W & Prchal, JT 2007, 'Imatinib effect on growth and signal transduction in polycythemia vera', Experimental Hematology, vol. 35, no. 6, pp. 931-938. https://doi.org/10.1016/j.exphem.2007.03.012
Gaikwad A, Verstovsek S, Yoon D, Chang KT, Manshouri T, Nussenzveig R et al. Imatinib effect on growth and signal transduction in polycythemia vera. Experimental Hematology. 2007 Jun 1;35(6):931-938. https://doi.org/10.1016/j.exphem.2007.03.012
Gaikwad, Amos ; Verstovsek, Srdan ; Yoon, Donghoon ; Chang, Ko Tung ; Manshouri, Taghi ; Nussenzveig, Roberto ; Cortes, Jorge ; Vainchenker, William ; Prchal, Josef T. / Imatinib effect on growth and signal transduction in polycythemia vera. In: Experimental Hematology. 2007 ; Vol. 35, No. 6. pp. 931-938.
@article{d2f4fb96891a4b1bbcc787f342a60bf2,
title = "Imatinib effect on growth and signal transduction in polycythemia vera",
abstract = "Objective: An activating mutation of Janus kinase 2 (JAK2) in majority of polycythemia vera (PV) and other myeloproliferative disorders was reported. As imatinib inhibits several tyrosine kinases, we studied its effect in PV. Patients and Methods: We employed FDCP reporter cells expressing wild-type JAK2 and mutant JAK2V617F to study the efficacy of imatinib by cell proliferation assay and its effect on several cell-signaling events. Imatinib's efficacy was also examined on in vitro expanded native human erythroid progenitors. In addition, analysis of the percent JAK2 T-allele and phospho-signal transducer and activator of transcription-5 (STAT5) in granulocytes of PV patients following imatinib therapy was assessed. Results: Imatinib showed a specific time- and dose-dependent growth inhibitory effect on FDCP cells expressing JAK2V617F, wherein we observed imatinib's inactivation of JAK2, STAT5 and cKIT proteins. In vitro expanded human PV erythroid progenitors were more sensitive to imatinib than normal erythroid progenitors and FDCP cells expressing JAK2V617F, with growth inhibition at concentrations attainable in vivo. In an ongoing clinical study, a PV patient showed strong correlation between the percent JAK2 T-allele and his responsiveness to imatinib therapy. Conclusion: Our data elucidate the therapeutic benefit of imatinib seen in some PV patients. Our data suggest that JAK2/STAT5 and cKIT activation may be integrated. To our knowledge, this is the first report demonstrating imatinib's effect on PV erythroid progenitors. These studies underscore the limitation of experiments using cell lines expressing the gene of interest.",
author = "Amos Gaikwad and Srdan Verstovsek and Donghoon Yoon and Chang, {Ko Tung} and Taghi Manshouri and Roberto Nussenzveig and Jorge Cortes and William Vainchenker and Prchal, {Josef T.}",
year = "2007",
month = "6",
day = "1",
doi = "10.1016/j.exphem.2007.03.012",
language = "English (US)",
volume = "35",
pages = "931--938",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Imatinib effect on growth and signal transduction in polycythemia vera

AU - Gaikwad, Amos

AU - Verstovsek, Srdan

AU - Yoon, Donghoon

AU - Chang, Ko Tung

AU - Manshouri, Taghi

AU - Nussenzveig, Roberto

AU - Cortes, Jorge

AU - Vainchenker, William

AU - Prchal, Josef T.

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Objective: An activating mutation of Janus kinase 2 (JAK2) in majority of polycythemia vera (PV) and other myeloproliferative disorders was reported. As imatinib inhibits several tyrosine kinases, we studied its effect in PV. Patients and Methods: We employed FDCP reporter cells expressing wild-type JAK2 and mutant JAK2V617F to study the efficacy of imatinib by cell proliferation assay and its effect on several cell-signaling events. Imatinib's efficacy was also examined on in vitro expanded native human erythroid progenitors. In addition, analysis of the percent JAK2 T-allele and phospho-signal transducer and activator of transcription-5 (STAT5) in granulocytes of PV patients following imatinib therapy was assessed. Results: Imatinib showed a specific time- and dose-dependent growth inhibitory effect on FDCP cells expressing JAK2V617F, wherein we observed imatinib's inactivation of JAK2, STAT5 and cKIT proteins. In vitro expanded human PV erythroid progenitors were more sensitive to imatinib than normal erythroid progenitors and FDCP cells expressing JAK2V617F, with growth inhibition at concentrations attainable in vivo. In an ongoing clinical study, a PV patient showed strong correlation between the percent JAK2 T-allele and his responsiveness to imatinib therapy. Conclusion: Our data elucidate the therapeutic benefit of imatinib seen in some PV patients. Our data suggest that JAK2/STAT5 and cKIT activation may be integrated. To our knowledge, this is the first report demonstrating imatinib's effect on PV erythroid progenitors. These studies underscore the limitation of experiments using cell lines expressing the gene of interest.

AB - Objective: An activating mutation of Janus kinase 2 (JAK2) in majority of polycythemia vera (PV) and other myeloproliferative disorders was reported. As imatinib inhibits several tyrosine kinases, we studied its effect in PV. Patients and Methods: We employed FDCP reporter cells expressing wild-type JAK2 and mutant JAK2V617F to study the efficacy of imatinib by cell proliferation assay and its effect on several cell-signaling events. Imatinib's efficacy was also examined on in vitro expanded native human erythroid progenitors. In addition, analysis of the percent JAK2 T-allele and phospho-signal transducer and activator of transcription-5 (STAT5) in granulocytes of PV patients following imatinib therapy was assessed. Results: Imatinib showed a specific time- and dose-dependent growth inhibitory effect on FDCP cells expressing JAK2V617F, wherein we observed imatinib's inactivation of JAK2, STAT5 and cKIT proteins. In vitro expanded human PV erythroid progenitors were more sensitive to imatinib than normal erythroid progenitors and FDCP cells expressing JAK2V617F, with growth inhibition at concentrations attainable in vivo. In an ongoing clinical study, a PV patient showed strong correlation between the percent JAK2 T-allele and his responsiveness to imatinib therapy. Conclusion: Our data elucidate the therapeutic benefit of imatinib seen in some PV patients. Our data suggest that JAK2/STAT5 and cKIT activation may be integrated. To our knowledge, this is the first report demonstrating imatinib's effect on PV erythroid progenitors. These studies underscore the limitation of experiments using cell lines expressing the gene of interest.

UR - http://www.scopus.com/inward/record.url?scp=34249019530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249019530&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2007.03.012

DO - 10.1016/j.exphem.2007.03.012

M3 - Article

C2 - 17533047

AN - SCOPUS:34249019530

VL - 35

SP - 931

EP - 938

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 6

ER -